Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma
BK Link, ZK Ballas, D Weisdorf… - Journal of …, 2006 - journals.lww.com
Abstract Oligodeoxynucleotides containing CpG motifs (CpG ODN) can alter various
immune cell subsets important in antibody therapy of malignancy. We undertook a phase I
trial of CPG 7909 (also known as PF-3512676) in patients with previously treated lymphoma
with the primary objective of evaluating safety across a range of doses, and secondary
objectives of evaluating immunomodulatory effects and clinical effects. Twenty-three patients
with previously treated non-Hodgkin lymphoma received up to 3 weekly 2-hour intravenous …
immune cell subsets important in antibody therapy of malignancy. We undertook a phase I
trial of CPG 7909 (also known as PF-3512676) in patients with previously treated lymphoma
with the primary objective of evaluating safety across a range of doses, and secondary
objectives of evaluating immunomodulatory effects and clinical effects. Twenty-three patients
with previously treated non-Hodgkin lymphoma received up to 3 weekly 2-hour intravenous …